期刊文献+

circ-0026462靶向miR-361-3p调控前列腺癌细胞对恩杂鲁胺耐药性的机制研究

circ-0026462 regulated the effect and mechanism of enzalutamide resistance in prostate cancer cells by targeting miR-361-3p
原文传递
导出
摘要 目的探讨circ-0026462靶向miR-361-3p调控前列腺癌细胞对恩杂鲁胺耐药性的机制研究。方法体外培养人前列腺癌细胞DU-145,建立前列腺癌恩杂鲁胺耐药性细胞DU-145/Enz,使用恩杂鲁胺处理DU-145、DU-145/Enz细胞,将其分为si-NC组、si-circ-0026462组、si-circ-0026462+anti-miR-NC组及si-circ-0026462+anti-miR-361-3p组。采用MTT法检测细胞的增殖能力;采用流式细胞术检测细胞凋亡率;采用qRT-PCR检测circ-0026462、miR-361-3p的表达量;采用双荧光素酶报告检测circ-0026462与miR-361-3p的靶向关系;采用Western blot法检测雄激素受体变异体(AR-V7)、细胞周期蛋白D1(Cyclin D1)、细胞周期蛋白依赖性抑制剂(P21)、B淋巴细胞瘤-2(Bcl-2)、Bcl-2相关蛋白(Bax)蛋白的表达量。结果与DU-145/Enz细胞比较,DU-145细胞的OD值及Cyclin D1、Bcl-2蛋白水平降低(均P<0.001),细胞凋亡率及P21、Bax蛋白水平升高(均P<0.001);与DU-145细胞比较,DU-145/Enz细胞中circ-0026462的表达水平升高(P<0.001),miR-361-3p的表达水平降低(P<0.001);转染si-circ-0026462可明显降低OD值、AR-V7、Cyclin D1及Bcl-2的表达水平(均P<0.001),提高细胞凋亡率及P21、Bax的表达水平(P<0.001);双荧光素酶报告实验证实circ-0026462可靶向结合miR-361-3p;抑制miR-361-3p表达可明显逆转沉默circ-0026462对DU-145/Enz细胞增殖、凋亡及耐药性的作用。结论沉默circ-0026462可通过上调miR-361-3p的表达而抑制细胞增殖及促进细胞凋亡,从而降低前列腺癌细胞对恩杂鲁胺的耐药性。 Objective To explore whether circ-0026462 regulated enzalutamide resistance in prostate cancer cells by targeting miR-361-3p.Methods Human prostate cancer cells DU-145 were cultured in vitro to establish prostate cancer enzalutamide-resistant cells DU-145/Enz,and enzalutamide was used to treat DU-145 and DU-145/Enz cells.si-NC,si-circ-0026462,si-circ-0026462 and anti-miR-NC,si-circ-0026462 and anti-miR-361-3p were transfected into DU-145/Enz cells respectively.MTT was used to detect cell proliferation ability.Flow cytometry was used to detect the apoptosis rate.qRT-PCR experiment was used to detect the expression level of circ-0026462 and miR-361-3p.The dual luciferase reporter experiment was used to detect the targeting relationship between circ-0026462 and miR-361-3p.Western blot method was used to detect the expression of AR-V7,Cyclin D1,P21,Bcl-2 and Bax protein.Results Compared with DU-145/Enz,the OD value and the protein levels of Cyclin D1 and Bcl-2 in DU-145 cells were decreased(all P<0.05),and the apoptosis rate and the protein levels of P21,Bax were increased(all P<0.05).Compared with DU-145,the expression level of circ-0026462 in DU-145/Enz cells was increased(P<0.05),and the expression level of miR-361-3p was decreased(P<0.05).Transfection of si-circ-0026462 could significantly reduce the OD value and the expression levels of AR-V7,Cyclin D1 and Bcl-2(all P<0.05),and increase the apoptosis rate and the expression levels of P21 and Bax(P<0.05).The dual luciferase report experiment confirmed that circ-0026462 could target miR-361-3p.Inhibition of miR-361-3p expression could significantly reverse the effects of silencing circ-0026462 on the proliferation,apoptosis and drug resistance of DU-145/Enz cells.Conclusions Silencing circ-0026462 could inhibit cell proliferation and promote cell apoptosis by up-regulating the expression of miR-361-3p,thereby reducing the resistance of prostate cancer cells to enzalutamide.
作者 万涛 周治军 徐康 杨军 熊标 Wan Tao;Zhou Zhijun;Xu Kang;Yang Jun;Xiong Biao(Department of Urology,the First People's Hospital of Tianmen,Tianmen 431700,China)
出处 《国际泌尿系统杂志》 2022年第5期797-802,共6页 International Journal of Urology and Nephrology
关键词 前列腺肿瘤 恩杂鲁胺 微小RNA-361-3p 环状RNA-0026462 Prostatic Neoplasms Enzalutamide MicroRNA-361-3p circRNA-0026462
  • 相关文献

参考文献3

二级参考文献42

  • 1宋丽君,王飏,陆旭芳,李志裕.雄激素受体拮抗剂MDV3100的合成研究[J].精细化工中间体,2012,42(1):34-36. 被引量:7
  • 2方习武,夏术阶,唐孝达.雄激素受体在人类前列腺癌发展中的作用研究[J].中国病理生理杂志,2004,20(7):1275-1279. 被引量:5
  • 3崔福德.药剂学[M].北京:人民卫生出版社,2008:311-314.
  • 4TRAN C,OUK S,CLEGG N,et al. Development of a second generation antiandrogen for treatment of ad- vanced prostate cancer [J]. Science,2009,324(5928).. 787-790.
  • 5CHARLES kS,MICHAEL EJ,CHARLIE DC,et al. Di- arylhydantoin Compounds: US, 7709517 [ P ].2010-05-04.
  • 6HOWARD L SCHER,KARIM FIZAZI,FRED SAAD, et al. Increased survival with enzalutamide in prostate af- ter chemotherapy[OL]. N Engl Med: 2012-8-15.
  • 7FOSSA SD, SLEE PH, Brausi M, et al. Flutamide versus prednisone in patients with prostate cancer symptomati- cally progressing after androgen-ablative therapy: a phase III study of the European organization for re- search and treatment of cancer genitourinary group [J]. J Clin Oncol,2001,19(1 ) :62-71.
  • 8AKAZA H,HINOTSU S,USAMI M,et al. Study group for the combined androgen blockade therapy of prostate cancer combined androgen blockade with hiealutamide for advanced prostate cancer: long-term follow-up of a phase 3,double-blind,randomized study for survival [ J ]. Cancer, 2009 ; 115 ( 15 ) : 3437-3445.
  • 9CRAWFORI) E D,EISENBERGER M A,MCLEOD DG,et al. A controlled trial of leuprolide with and with- out flutamide in prostatic carcinoma[J]. N Engl J Med, 1989,321 (7) :419-424.
  • 10CHEN CD,WELSBIE DS,TRAN C,et al. Molecular determinants of resistance to antiandrogen therapy [J]. Nat Med, 2004,10( 1 ) : 33-39.

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部